SidekickHealth begins PAD partnership with Bayer


Nordic digital therapeutics company SidekickHealth has begun a strategic partnership with German pharma Bayer to provide a digital medication management and lifestyle change platform to patients suffering from peripheral artery disease (PAD).

Sidekick specialises in gamified digital therapeutic (DTx) solutions and programmes, transforming chronic disease management across multiple therapeutic areas in alliance with key stakeholders in the pharmaceutical and healthcare industries.

PAD is a chronic disease, which significantly reduces the quality of life of sufferers and the World Health Organization claims that a lack of support for people with vascular diseases including PAD, exposes them to acute and even fatal cardiovascular events.

Sidekick and Bayer have agreed to launch the program in Sweden, aiming to roll it out in other European markets.

Sidekick’s clinically validated digital platform has a demonstrated history in helping people modify their behaviour, increase medical adherence and better manage chronic illnesses and symptoms.

The latest partnership will also involve collaborating with key opinion leaders and clinical experts in PAD, such as the president of the Swedish Society of Vascular Surgery, Dr Carl Wahlgren.

Tryggvi Thorgeirsson, co-founder and CEO of SidekickHealth, said: “Bayer continues to be at the forefront in the transformation of medicine, and we are thrilled to partner with them to deliver innovative therapies for people with lifestyle-related diseases.

“Lifestyle change is at the heart of what we do, and our programs can have a multiplier effect on the positive outcomes of medical care and the world’s best medicines.”

“We reinforce medication adherence and use it as a gateway to bring about positive lifestyle change in a much broader sense. We are excited to be working with Bayer to help patients take that first step and beyond.”

SidekickHealth has been rated in the top 0.1% in quality by the industry’s leading rating company ORCHA and boasts successful customer launches across multiple therapeutic areas – ranging from type 2 diabetes, ulcerative colitis and smoking cessation.

Earlier this year, Sidekick entered into an agreement with New York-listed Pfizer to develop a DTx smoking cessation solution in partnership with the pharmaceutical giant’s Austrian unit.